Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Xspray, Press Conference

By Inderes8/20/2026, 7:00 AM
Xspray Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Blake Leach
00:00 - 24:51

Good morning, investors and media, and thank you for the strong participation this morning. As mentioned, I'm Blake Leach, CEO of Xspray, and I thank Jacob and Sofia for helping to moderate today's call. Today I am here to provide color to the CRL announced yesterday and help to answer questions you may have. Before I get into that, I just want to pause and step back. 20 years ago this summer, Sprycel was approved in America. Sprycel helped to turn a once life-changing condition into a manageable, near-normal life expectancy. Dasatinib remains today a key treatment option in leukemia. Last year alone, revenues of Dasatinib were about 1.9 billion USD. And yet the medical need for improved dasatinib after 20 years is clear. Dasatinib has demonstrated bioequivalence at a 30% lower dose and is designed to enable concomitant use with acid-reducing medicines. This is an important benefit to patients, nurses, and physicians. Our view of the dasatinib landscape is unchanged. The CRL does not change our view of the potential of Dasanib. Certainly not of the high-net platform technology, nor the commercial opportunity ahead. The remaining issue is still centered on the regulatory status at Near Pharma, which has been known to the market and is ultimately in the FDA's hands. But this is not a new fundamental problem. We have previously communicated that the approval of Dasynoc remains dependent on the resolution of the outstanding regulatory requirements related to Neopharm, and that the timing of FDA processes cannot be controlled or guaranteed by Xspray. Now, in the Q2 report a couple of weeks ago, I outlined that this could be time-sensitive and tight. Ahead of the August 25th date, we stated that the FDA could issue a CRL because the inspection of the facility had not yet been completed, while a Nyr Pharma clearance during the autumn would likely be consistent with launch readiness. The additional batch data request that was received within the CRL is absolutely manageable in substance. We already believe that the submitted quality package is strong and within the FDA's expectations. What the FDA is asking for now is more commercial-scale evidence, which just means producing and documenting additional batches that were, in any case, part of our launch preparation. I also want to highlight what was not in the CRL; there were no questions related to bioavailability, bioequivalence, stability, or the risk of medication errors, as was evident in previous calls, which indicates that we have now resolved these lingering issues. So this is not a product quality problem, and it does not change at all our clinical or commercial rationale. The benefits of Dasatinib are very strong, both in bioequivalence and with acid-reducing medicines. Today we remain focused on the bigger vision, bringing improved treatments to patients while preparing for a rapid launch. Once the remaining regulatory requirements are resolved, the batch work will be accelerated so that we can ensure that we are able to resubmit in 2026. We are ready to commercialize once we have clearance, and we have EverSana already at our side and ready to start our US commercial operations and organization once that occurs. So thank you. Those are my opening remarks. And Sofia and Jacob, I would like to open up to questions, please. If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Philip Einarson from Redeye. Please go ahead. Hi, everybody. Thank you for taking my questions. I want to start off on the batch data. And maybe if you could just clarify a little bit further, what sort of data is it that has been requested and if it will require several batches? Thank you. What is requested is commercial-scale consecutive batch data. Now, as we are preparing for commercial launch, this was obviously within our anticipated development plans this fall. The request is not surprising for us. And whilst we do have plans to provide these commercial batches, we will now evaluate how we can accelerate that together with our partner to ensure that we can develop the resubmission as quickly as possible. Right, so a follow-up to that would be, do you have any sort of estimate of how long that process would be from where we stand right now to produce these batches that would be required. At the current moment. We are working with our partners at NRx Pharmaceuticals; I can assure you and the market that we have an expedited time frame already under development, and we will aim to complete this as soon as possible in the coming weeks. Okay, the next one then, maybe if you could clarify the issues that have been resolved in this CRL compared to the last. To be very clear, one of the major questions that was provided in a previous CRL related to the risk of medication error that has been substantially addressed through our resubmission in February, and it no longer features in the discussion with the FDA as outlined in the CRL. Okay, good. And so the last one for me: with this extended timeline, should we expect a down-prioritization of Excess-008 and A025 to further reserve the cash runway? Any comment on that? Yes, thank you. It is a good point indeed. Yes, I think our resources will be focused to ensure that we realize the launch of our two products that are currently undergoing FDA review, those being the designated assets. And at the same time, we need to balance that with our commercial readiness, and we will continue to be vigilant in our capital expenditure to focus on driving forward the portfolio and ensuring that we are commercially ready so that we are not delayed upon commercial launch. Okay. Thank you all from me. Thank you. As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions or closing comments. Thank you, Sophia, this is Jacob. I have the written questions in front of me, and there are a number of questions, some of which are quite long and cover the same topics that we already touched upon. So I will try to do my best to extract the parts that we did not already cover. Thomas Plot has posted a number of questions concerning the batch manufacturer. And just to clarify, one of the questions is: did you already manufacture batches or is this something that we need to do from scratch with Neuraxpharm? We are, in fact, Jacob, and thank you. We have produced multiple batches through the course of the development of Daznok. And in fact, we also, as part of our resubmission in February, appended five batches that were developed post the implementation of our corrective actions. So the development of new batches or the request for consecutive commercial-scale batches, which is really what the FDA is asking for, is within our operating plan already, and we will continue to accelerate and ensure that we develop these as we move forward quickly. And there is also a detailed question here about the timing that might have some value, regarding whether commercial scale batches were manufactured after the CAPA activities were completed as part of the remediation plan before the CRL was received. No, the answer to that is no, they were not. No, they have not been. That is why we have that activity already planned for within our commercial scale-up activities. Moving on to Near Pharma. Thomas Clot again has a question whether we anticipate that the FDA will need to conduct a new inspection. Or is it possible that they could resolve it based on the documentation and commercial batch data? He does not mention the previous inspection, but I suppose that is also included in the alternatives. Can you shed some light on what we know about that? At this point, we are anticipating a response and a decision from the FDA as it relates to the OAI status at Near Pharma. That decision is within the FDA's purview to make, as you indicated, Efor completed an inspection earlier this year in May, in fact, with an outcome that was positive, as our partners at Benton Group and Near Pharma have communicated to us and I have communicated previously to the market. So at this point, we are waiting for the FDA's decision on whether or not they require an additional inspection and or if they would rely on the information that potentially would be provided from a mutual recognition route. But at this point, I do not want to speculate on timing or, certainly, the FDA's decision. Yes, I understand, and timing is, of course, an issue that concerns many of the people asking questions. There is also one wanting to specify, assuming the required commercial batches can be manufactured without issues, what is your current realistic timeline for submitting the response to the FDA? What do we say about that? What can we say about that? Well, I can certainly say that we expect to resolve this batch data question and work stream within the coming weeks, and that we anticipate resubmitting in 2026. Yes, the same person also observed that the previous CRL for Nul also requested additional information from commercial scale manufacturing. And how do those two relate to each other? I think the question is to what extent can those be coordinated or can they even be done simultaneously. Done simultaneously. It is important to note that we have the same factory that underpins both development programs. Near Pharma is our third-party contractor that is helping us to develop both the key opportunity in front of us for Daznock. The questions that were raised in the CRL relate to the Dasanoc dossier and are not linked to PKI. As you may recall, Nucala has had different questions that are being addressed at this moment. So we again will be focusing our manufacturing activity in the coming weeks to satisfy our needs for commercial scale manufacturing of both products. And thank you. I think the questions that I have in front of me now are on the same topics. So, let me have just a brief moment to see the time. Yes, we do have some questions from several people about financing. Is the current cash position sufficient to reach approval and launch? And more specifically. There is a person asking. Whether we should anticipate a new share issue ahead of the upcoming scheduled dates. And what is your comment on that? Well, it is an important question. And I thank the person for submitting it. We have consistently communicated, both in our recent quarterly reports and annual reports, that our future capital requirements depend on several factors, including, obviously, our regulatory timelines, the launch timelines, the commercial uptake activities, and the development activities. Our cash position, as stated in the Q2 report, remains unchanged. We will execute and maintain our financial stewardship to balance the necessary development and manufacturing requirements in the short term while maintaining our operational readiness for launch. We have also communicated that additional financing would be required to support our commercialization and launch planning. We continue to monitor this very closely and evaluate different financing alternatives, including the potential of any capital raise. But we are pleased with the strong support that we have received from our major shareholders in previous financing and their ongoing and continuous support to our business and our development pathway. I would like to add that the CRL today, as it relates to financing, does not require a new development program. It means producing, testing, and compiling the quality review additional requirements needed in commercial scale batch data. Since these were already part of our launch preparation, the issue is manageable. Thank you, Jacob. Thank you, Blake. So, a lot of interest and a lot of questions. We have already covered several of them. And I am trying to orient myself around this. We do get questions about whether we anticipate a class one or class two review, meaning the timeline from resubmission to the PDUFA date from the FDA, whether it will be 2 or 6 months. So we have those questions. So would you like to respond to that? So I mean, obviously we are extremely keen to ensure that we have the shortest and the fastest route through to an approval for both Norlevo and Norlevo for Dasani. I do not want to speculate whether it would be a Class 1 or a Class 2 review. Our focus today is making sure that we deliver, analyze, and manufacture these consecutive commercial scale batches. Do that quickly in partnership with the new owners at Venta and Near Pharma, and make sure that we are able to satisfy the additional data that the FDA has requested. Right. There are actually two questions here that I would have thought were covered. But maybe; they are quite important to have clarified. So I think we should go over them again. One is that you said you plan to resubmit the NDA as soon as possible, but can you and will you be able to file it before the status of the Nevada facility and the clearance of the GMP issues have been resolved? Yeah, so maybe we can start by clarifying the answer to that. Can we resubmit, or do we have to wait for the resolution of the GMP issues at the pharma? Or can we resubmit while that is still pending? I think the key point here is that the principal bottleneck remains Near Pharma's regulatory status, and we've communicated that before. And that is not directly within our control. And what we will aggressively manage is the manufacturing of these consecutive commercial batches and the data packages that accompany them. And that is what we are focusing on today. Once that is done, we can resubmit the NDA without waiting for the GMP issues to be resolved. Right. We won't receive an approval until both items are satisfied. But the question is whether we can resubmit the application. The application will require both the approval from the FDA regarding Neopharma, as well as the acceptance of the data that we are providing related to these additional consecutive commercial-scale batches. Yes. Okay. And Hunter Capital asks, are we looking at additional studies? That one is easy to address. I think at this point there is no requirement for additional studies as I mentioned, on the contents of the CRL, or as it relates to the previous CRLs that we've also addressed. So this question for additional studies is actually not something that we are looking at today. Yes, we also have some questions from several angles. Is it necessary or possible to change to a third-party manufacturer? Second source manufacturing has been on our radar. Jacob and team for quite some time. As you know, we had initiated work at a site in 2020. But every capital decision is measured against one question. Does this bring these two assets closer to approval or not? A new facility takes roughly 18 months or more to become operational. Funding that, instead of funding launch readiness, would push out a PDUFA date for both products. It does not advance it, and has consistently sat somewhere between 6 to 12 months ahead of the next regulatory milestone. So we have been prioritizing the approval path appropriately before parallel infrastructure development. That said, we do continuously review our supply chain on all aspects to ensure that we have the right operating model and the right redundancy moving forward. It's not an oversight. Right, I thank everyone for posting so many questions; I struggled a little bit to make sure that nothing slips by. I admit it is a little bit of a struggle to make sure that nothing slips by. But I think we covered the essence of what's been posted in the chat. So I think we can wrap up the Q&A portion. Blake, okay. Thank you. Jacob, thank you, Sophia. I'd like to close by just reiterating the main point here, which is that this CRL does not change our view of danavoreb. About Dasanib or the commercial opportunity. Dasanib is a nearly 2 billion US dollar market today. We are gating items that are in front of us related to Near Pharma's FDA status. The market knew, and we know, that it was time-sensitive. The additional batch data request is manageable documentation. We expect to address this requirement as part of our launch preparation work, which is already underway and will continue into early October. I am pleased to also share with the community that I am planning an investor update presentation at a CML conference, which will be hosted in Gothenburg. The Goldman conference is October 1st, and the dates and details will follow as we confirm them. But in the meantime, I do look forward to your continued support and remain assured that we will continue to advance, both rationally and in parallel, and drive forward to unlock the potential in front of us. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…